386 related articles for article (PubMed ID: 28056752)
21. HBV cure: why, how, when?
Levrero M; Testoni B; Zoulim F
Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
[TBL] [Abstract][Full Text] [Related]
22. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
Kao JH
Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
[TBL] [Abstract][Full Text] [Related]
24. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
Al Ashgar H; Peedikayil MC; Al Quaiz M; Al Sohaibani F; Al Fadda A; Khan MQ; Thoralsson E; Al Thawadi S; Al Jedai A; Al Kahtani K
Saudi J Gastroenterol; 2017; 23(3):190-198. PubMed ID: 28611343
[TBL] [Abstract][Full Text] [Related]
25. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
26. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
Lu J; Zhang S; Liu Y; Du X; Ren S; Zhang H; Ma L; Chen Y; Chen X; Shen C
Liver Int; 2015 Jun; 35(6):1692-9. PubMed ID: 25438657
[TBL] [Abstract][Full Text] [Related]
27. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
28. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
29. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
[TBL] [Abstract][Full Text] [Related]
30. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
31. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
Pei Y; Wang C; Yan SF; Liu G
J Med Chem; 2017 Aug; 60(15):6461-6479. PubMed ID: 28383274
[TBL] [Abstract][Full Text] [Related]
32. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Chevaliez S; Hézode C; Bahrami S; Grare M; Pawlotsky JM
J Hepatol; 2013 Apr; 58(4):676-83. PubMed ID: 23219442
[TBL] [Abstract][Full Text] [Related]
33. Current treatments for chronic hepatitis B virus infections.
Zoulim F; Lebossé F; Levrero M
Curr Opin Virol; 2016 Jun; 18():109-16. PubMed ID: 27318098
[TBL] [Abstract][Full Text] [Related]
34. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
[TBL] [Abstract][Full Text] [Related]
35. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy.
Li MH; Yi W; Zhang L; Lu Y; Lu HH; Shen G; Wu SL; Hao HX; Gao YJ; Chang M; Liu RY; Hu LP; Cao WH; Chen QQ; Li JN; Wan G; Xie Y
J Viral Hepat; 2019 Jul; 26 Suppl 1():32-41. PubMed ID: 31380582
[TBL] [Abstract][Full Text] [Related]
36. Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B.
Chen X; Chen X; Chen W; Ma X; Huang J; Chen R
J Med Virol; 2014 Oct; 86(10):1705-13. PubMed ID: 24980710
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y
Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987
[TBL] [Abstract][Full Text] [Related]
39. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
[TBL] [Abstract][Full Text] [Related]
40. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]